Welcome to the Stephen J. Ryan
Initiative for Macular Research
Exciting news! We are changing the program name to honor our founder, Steve Ryan. More...
The new name is effective immediately, and will be fully implemented across the program’s website and communications before the program’s 9th annual conference in January, 2017.
The Stephen J. Ryan Initiative for Macular Research (RIMR) brings together outstanding basic scientists, engineers, medical researchers, and clinicians to develop a better understanding of age-related atrophic macular degeneration (AMD). At annual RIMR conferences, these accomplished leaders from very different backgrounds and disciplines explore technologies, discoveries, and ideas. By sharing their diverse perspectives in interdisciplinary discussions and research collaborations, RIMR participants are improving AMD diagnostics, and expanding the prospect of new treatments for the number one cause of visual impairment and blindness in older Americans.
Age-related macular degeneration
Age-related macular degeneration is a leading cause of vision loss in America today. AMD is a disease of aging that affects the macula; the region of the retina responsible for sharp, central vision. AMD occurs in two forms: dry (or atrophic) and wet (or neovascular). Atrophic macular degeneration accounts for more than 85% of patients diagnosed with AMD which affects more than 10 million Americans. Due to the rapid aging of the US population, this number will increase dramatically by 2020. Early and intermediate forms of dry/atrophic AMD are the most common forms of AMD; however, progression of dry AMD into one of two advanced forms of the disease leads to blindness. Advanced wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula and leak blood and fluid.
Research across disciplines has led to the development of effective drugs for wet AMD that for the first time in history, improve vision in these patients. Advanced dry/atrophic AMD, also known as geographic atrophy, results in extensive loss of the retinal pigment epithelium in the macula and overlying photoreceptors. Despite advances in the treatment of wet AMD, no such effective treatments are available for atrophic AMD. However, bringing together great scientists and innovative new technologies from different disciplines has the potential for unprecedented success.